Acetyl-leucine in Post-stroke Ataxia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT07275749

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07275749
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07275749. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-01 (anticipated); primary completion 2026-07-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Acetyl-leucine in Post-stroke Ataxia
Intervention (Drug)
Acetyl-Leucine
Intervention (Drug)
Placebo
Intervention (Drug)
Clopidogrel 75 Mg Oral Tablet
Intervention (Drug)
aspirin 100mg
Lead sponsor
Kafrelsheikh University (class: other)

Record details

Record id
cardio:ct-nct07275749
Content hash
edb130a6b2cdce7d8ae8c8a22495dfab640ffaaceffcdd7b7248a45f0fe912f4